Skip to main content
. 2018 Mar 22;9:13–21. doi: 10.1016/j.omto.2018.03.001

Figure 6.

Figure 6

CF33-Fluc Shows Anti-tumor Activity in HCT116 Xenograft Model following Intratumoral and Intravenous Delivery

Both IV (B) (eight mice/group with four sacrificed at day 10) and IT (A) (five mice/group with two sacrificed at day 10) delivery methods result in tumor growth abrogation compared to controls (four mice for IV PBS control, and two mice for IT control). Both IT and IV treatment groups had individual mice with complete pathologic tumor regression. *IT p = 0.037; *IV p = 0.034.